Objective To explore the serum levels of ROS modulator 1 (ROMO1), reactive oxygen species (ROS) and C-reactive protein (CRP) in patients with hepatoblastoma (HB) and their correlation with clinicopathological features. Methods Seventy-four HB children admitted to Jinan People's Hospital and Jinan Second Maternal and Child Health Hospital from September 2019 to June 2024 were selected as the study objects and included in the hepatoblastoma group, and 70 healthy patients admitted to the hospital for examination during the same period were selected as the healthy group. The serum levels of ROMO1, ROS and CRP were detected and compared between the two groups. The serum levels of ROMO1, ROS and CRP in HB patients were further analyzed under different clinicopathological characteristics. The correlation between serum levels of ROMO1, ROS, CRP and the severity of the disease was analyzed by Spearman. ROC curve analysis was performed to evaluate the diagnostic efficacy of ROMO1, ROS, and CRP levels in HB. Results The serum ROMO1, ROS and CRP levels in HB patients were significantly higher than those in the healthy group [(131.74±9.83 vs 92.63±7.71) pg/mL, (286.15±25.47 vs 236.82±15.69) nmol/mL, (6.83±2.03 vs 4.89±1.15) mg/L], the difference was statistically significant; There was no significant difference in serum levels of ROMO1, ROS and CRP among HB patients with different tumor diameter and pathological type. and the differences in serum ROMO1, ROS, and CRP levels among patients with different alpha-fetoprotein, TNM staging, degree of differentiation, and tumor invasion or metastasis were statistically significant; Spearman correlation analysis showed that serum ROMO1, ROS, CRP levels were significantly positively correlated with TNM stage (r=0.8757, 0.8392, 0.8109, P<0.001). The ROC curve analysis results showed that the single detection and combined diagnosis of serum ROMO1, ROS, CRP all have certain diagnostic value for HB, and the combined diagnostic efficiency of the three items [AUC: 0.992 (0.863-0.981), P<0.05] is significantly higher than that of single diagnosis. Conclusions The elevated levels of serum ROMO1, ROS, and CRP in patients with HB are positively correlated with the severity of the disease and have certain diagnostic value for HB. They may be important parameters for monitoring the severity of HB and treatment efficacy.
Key words
hepatoblastoma /
reactive oxygen species modulator 1 /
reactive oxygen species /
C-reactive protein
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] ZHANG Y, SOLINAS A, CAIRO S, et al.Molecular Mechanisms of Hepatoblastoma[J]. Semin Liver Dis, 2021, 41(1): 28-41.
[2] WU Z, XIA F, WANG W, et al.Worldwide burden of liver cancer across childhood and adolescence, 2000-2021: a systematic analysis of the Global Burden of Disease Study 2021[J]. EClinicalMedicine, 2024, 75: 102765.
[3] LIM I, BONDOC A J, GELLER J I, et al.Hepatoblastoma-The Evolution of Biology, Surgery, and Transplantation[J]. Children (Basel), 2018, 6(1): 1.
[4] HAFBERG E, BORINSTEIN S C, ALEXOPOULOS S P.Contemporary management of hepatoblastoma[J]. Curr Opin Organ Transplant, 2019, 24(2): 113-117.
[5] ZHENG C, YE S, LIU W, et al.Prognostic value of systemic inflammation response index in hepatoblastoma patients receiving preoperative neoadjuvant chemotherapy[J]. Front Oncol, 2023, 13: 1276175.
[6] FUCHS J, RABAUX-EYGASIER L, RUPING F, et al.Reappraisal of liver resection as an alternative to transplantation in locally advanced hepatoblastoma: A systematic review and analysis of pooled individual patient data[J]. Pediatr Blood Cancer, 2024, 71(12): e31339.
[7] DEMBOWSKA-BAGINSKA B, WIECKOWSKA J, BROZYNA A, et al.Health Status in Long-Term Survivors of Hepatoblastoma[J]. Cancers (Basel), 2019, 11(11): 1777.
[8] JAMAR N H, KRITSILIGKOU P, GRANT C M.The non-stop decay mRNA surveillance pathway is required for oxidative stress tolerance[J]. Nucleic Acids Res, 2017, 45(11): 6881-6893.
[9] WANG L, LIU X, LIU Z, et al.Network models of prostate cancer immune microenvironments identify ROMO1 as heterogeneity and prognostic marker[J]. Sci Rep, 2022, 12(1): 192.
[10] AMINI M A, TALEBI S S, KARIMI J.Reactive Oxygen Species Modulator 1 (ROMO1), a New Potential Target for Cancer Diagnosis and Treatment[J]. Chonnam Med J, 2019, 55(3): 136-143.
[11] KINOSHITA T, GOTO T.Links between Inflammation and Postoperative Cancer Recurrence[J]. J Clin Med, 2021, 10(2): 228.
[12] HART P C, RAJAB I M, ALEBRAHEEM M, et al.C-Reactive Protein and Cancer-Diagnostic and Therapeutic Insights[J]. Front Immunol, 2020, 11: 595835.
[13] RI M, TZORTZAKAKIS A, SOTIROVA I, et al.CRP as an early indicator for anastomotic leakage after esophagectomy for cancer: a single tertiary gastro-esophageal center study[J]. Langenbecks Arch Surg, 2023, 408(1): 436.
[14] 倪鑫. 儿童肝母细胞瘤诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2019, 35(11): 2431-2434.
[15] MORIN C E, ARTUNDUAGA M, SCHOOLER G R, et al.Imaging for Staging of Pediatric Abdominal Tumors: An Update, From the AJR Special Series on Cancer Staging[J]. AJR Am J Roentgenol, 2021, 217(4): 786-799.
[16] REN H, ZHUO Z J, DUAN F, et al.ALKBH5 Gene Polymorphisms and Hepatoblastoma Susceptibility in Chinese Children[J]. J Oncol, 2021, 2021: 6658480.
[17] HOOKS K B, AUDOUX J, FAZLI H, et al.New insights into diagnosis and therapeutic options for proliferative hepatoblastoma[J]. Hepatology, 2018, 68(1): 89-102.
[18] CARRILLO-REIXACH J, TORRENS L, SIMON-COMA M, et al.Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications[J]. J Hepatol, 2020, 73(2): 328-341.
[19] SUN R, LI S, ZHAO K, et al.Identification of Ten Core Hub Genes as Potential Biomarkers and Treatment Target for Hepatoblastoma[J]. Front Oncol, 2021, 11: 591507.
[20] LIU W, CHEN S, LIU B.Diagnostic and prognostic values of serum exosomal microRNA-21 in children with hepatoblastoma: a Chinese population-based study[J]. Pediatr Surg Int, 2016, 32(11): 1059-1065.
[21] ZHENG D, LIU J, PIAO H, et al.ROS-triggered endothelial cell death mechanisms: Focus on pyroptosis, parthanatos, and ferroptosis[J]. Front Immunol, 2022, 13: 1039241.
[22] CHEUNG E C, VOUSDEN K H.The role of ROS in tumour development and progression[J]. Nat Rev Cancer, 2022, 22(5): 280-297.
[23] KUO C L, PONNERI B A, LIN Y C, et al.Mitochondrial oxidative stress in the tumor microenvironment and cancer immunoescape: foe or friend?[J]. J Biomed Sci, 2022, 29(1): 74.
[24] JO M J, KIM B G, PARK S H, et al.Romo1 Inhibition Induces TRAIL-Mediated Apoptosis in Colorectal Cancer[J]. Cancers (Basel), 2020, 12(9): 2358.
[25] SUN G, CAO Y, QIAN C, et al.Romo1 is involved in the immune response of glioblastoma by regulating the function of macrophages[J]. Aging (Albany NY), 2020, 12(2): 1114-1127.
[26] YE L, MAO S, FANG S, et al.Increased Serum Romo1 Was Correlated with Lung Function, Inflammation, and Oxidative Stress in Chronic Obstructive Pulmonary Disease[J]. Inflammation, 2019, 42(5): 1555-1560.
[27] WANG M, CHEN S, HE X, et al.Targeting inflammation as cancer therapy[J]. J Hematol Oncol, 2024, 17(1): 13.
[28] IKWEGBUE P C, MASAMBA P, OYINLOYE B E, et al.Roles of Heat Shock Proteins in Apoptosis, Oxidative Stress, Human Inflammatory Diseases, and Cancer[J]. Pharmaceuticals (Basel), 2017, 11(1): 2.
[29] LV J, WU Y, LI W, et al.High Expression of ROMO1 Aggravates the Malignancy of Hepatoblastoma[J]. J Oncol, 2021, 2021: 2341719.
[30] SATO Y, KOKUBU A, FUKUSHIMA K, et al.Fluctuations in C-reactive protein in a hepatoblastoma patient with thrombocytosis[J]. Clin Pract, 2011, 1(3): e56.
PDF(2171 KB)
